Skip to main content
Premium Trial:

Request an Annual Quote

Chip-Man’s Cell-IQ Tech to Be Used With TCS CellWorks’ AngioKit

NEW YORK, June 14 (GenomeWeb News) - Aiming to increase content and throughput in angiogenesis research, Chip-Man Technologies' Cell-IQ continuous cell culturing platform will now be used with TCS CellWorks' AngioKit model, the companies said today.

 

Cell-IQ is a continuous cell-culturing platform that enables real-time analysis of morphological and physiological events in living cells, co-cultures, primary cells, and monolayer tissue models. Chip-Man claims the technology "learns to identify, follow and measure morphological change in individual cells without traditional labels or dyes."

 

TCS CellWorks' AngioKit, meantime, uses human cell-lines to offer a cell-based system that quantitatively assesses pro- and anti-angiogenic agents, the company said. The kit is provided in 24-well plate format and is suitable for low volume screening applications.

 

According to TCS CellWorks CEO Terry Cartwright, the alliance "raises our ability to track cell proliferation, migration and differentiation within a complex co-culture model to a new level."

 

Chip-Man CEO Juha Korpinen said: "We welcome the opportunity to work with TCS CellWorks. They have a range of products to which Cell-IQ will bring additional value."

 

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.